

FILING DATE



UNITED STATE DEPARTMENT OF COMMERCE Pat nt and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

S EXAMINER

09/110,376

APPLICATION NO.

05/12/98

COHEN

HM12/1213

FIRST NAMED INVENTOR

THE LAW OFFICE OF JAMES C SIMMONS 11 FALMOUTH LANE WILLIAMSVILLE NY 14221 EYLER, Y

ART UNIT PAPER NUMBER

1642

DATE MAILED:

12/13/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks





Office Action Summary

Application No. 09/110,376 Applicăni(s)

Examiner

Yvonne Eyler

Group Art Unit 1642

Cohen et al.

Responsive to communication(s) filed on	
☐ This action is FINAL .	
Since this application is in condition for allowance except for f in accordance with the practice under Ex parte Quayle, 1935	
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	respond within the period for response will cause the
Disposition of Claims	
X Claim(s) 1-5	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	
Claim(s)	
Claim(s)	
☑ Claims 1-5	
Application Papers See the attached Notice of Draftsperson's Patent Drawing The drawing(s) filed on is/are objecte The proposed drawing correction, filed on The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority u All Some* None of the CERTIFIED copies of received received in Application No. (Series Code/Serial Number of the Certified copies not received: Acknowledgement is made of a claim for domestic priority	is approved disapproved. is approved disapproved. Inder 35 U.S.C. § 119(a)-(d). the priority documents have been ber) nternational Bureau (PCT Rule 17.2(a)).
Attachment(s)	
 Notice of References Cited, PTO-892 □ Information Disclosure Statement(s), PTO-1449, Paper No □ Interview Summary, PTO-413 □ Notice of Draftsperson's Patent Drawing Review, PTO-948 □ Notice of Informal Patent Application, PTO-152 	
SEE OFFICE ACTION ON TH	HE FOLLOWING PAGES



Application/Control Number: 09/110376

Art Unit: 1642

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claim 1, drawn to a method of predicting tumor metastasis, classified in class 435, subclass 7.23.
 - II. Claims 2-4, drawn to a method of tumor treatment, classified in class 424, subclass 130.1.
 - III. Claim 5, drawn to a xenographic method of prediction of metastasis, classified in class 424, subclass 93.1.
- 2. The inventions are distinct, each from the other because of the following reasons:
- 3. The inventions of Groups I, II, and III are each drawn to entirely different methods having completely different method steps, requiring completely different method compositions, and having different end goals and mechanisms of action. The method of Group I will not effect treatment of a tumor while the method of Group II does not predict metastasis. The methods of Groups I and III both predict metastasis, but require completely different compositions and steps which are not interchangeable and thus require unique searches and considerations. The method of Group II differs from that of Group III in that it will not predict an outcome.
- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/110376

Art Unit: 1642

5. Because these inventions are distinct for the reasons given above and the search required

Page 3

for any single Group is not required for any other Group, restriction for examination purposes as

indicated is proper.

6. This application contains claims directed to the following patentably distinct species of the

claimed invention:

The invention of Group II is further drawn to the following distinct species:

a) anti-ZAP compounds

b) anti-SYK-B compounds.

Each of the two species is drawn to a completely different compound with completely different chemical and biological characteristics and requiring non-cohesive searches and considerations.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations

Application/Control Number: 09/110376

Art Unit: 1642

of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yvonne Eyler, Ph.D. whose telephone number is (703) 308-6564. The examiner can normally be reached on Monday through Friday from 830am to 630pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Paula Hutzell, can be reached on (703) 308-4310. The fax phone number for this Group is (703) 305-3014 or (703) 308-4242.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [paula.hutzell@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Art Unit: 1642

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Yvonne Eyler, Ph.D.
Primary Examiner
December 6, 1999